• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Hepatitis C Diagnosis Treatment Market

    ID: MRFR/MED/1040-HCR
    90 Pages
    Kinjoll Dey
    September 2025

    Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Hepatitis C Diagnosis and Treatment Market Research Report - Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Hepatitis C Diagnosis Treatment Market Summary

    The Global Hepatitis C Diagnosis and Treatment Market is projected to grow significantly from 46.5 USD Billion in 2024 to 117.4 USD Billion by 2035.

    Key Market Trends & Highlights

    Hepatitis C Diagnosis and Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 8.78 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 117.4 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 46.5 USD Billion, reflecting the current demand for hepatitis C diagnosis and treatment solutions.
    • Growing adoption of innovative treatment modalities due to increasing prevalence of hepatitis C is a major market driver.

    Market Size & Forecast

    2024 Market Size 46.5 (USD Billion)
    2035 Market Size 117.4 (USD Billion)
    CAGR (2025-2035) 8.78%

    Major Players

    Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Incorporated, Gilead Sciences, Inc., AbbVie Inc., Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Abbott, Beckman Coulter, Inc., Siemens Medical Solutions USA, Inc., MedMira Inc., GlaxoSmithKline PLC, DiaSorin SpA, Qiagen, bioMérieux SA, Hologic, Inc., Bio-Rad Laboratories, Inc.

    Hepatitis C Diagnosis Treatment Market Drivers

    Market Growth Projections

    Emergence of Direct-Acting Antivirals

    The emergence of direct-acting antivirals (DAAs) has revolutionized the treatment landscape for Hepatitis C, significantly impacting the Global Hepatitis C Diagnosis and Treatment Market Industry. DAAs offer high cure rates and shorter treatment durations compared to traditional therapies, making them a preferred choice for patients and healthcare providers. The introduction of these innovative therapies has not only improved patient outcomes but also increased the overall treatment uptake. As a result, the market is witnessing a shift towards more effective treatment modalities, which is expected to drive growth in the coming years. The ongoing development of new DAAs further indicates a promising future for Hepatitis C treatment.

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic methods are transforming the landscape of the Global Hepatitis C Diagnosis and Treatment Market Industry. Innovations such as point-of-care testing and non-invasive diagnostic tools enhance the speed and accuracy of Hepatitis C detection. For instance, the development of rapid antibody tests and advanced molecular techniques allows for timely diagnosis, which is crucial for effective treatment initiation. These advancements not only improve patient outcomes but also facilitate broader screening initiatives, potentially reducing the burden of the disease. As the market evolves, the integration of these technologies is expected to contribute significantly to the anticipated growth, with projections indicating a market size of 117.4 USD Billion by 2035.

    Rising Global Prevalence of Hepatitis C

    The increasing prevalence of Hepatitis C globally serves as a primary driver for the Global Hepatitis C Diagnosis and Treatment Market Industry. As of 2024, approximately 71 million individuals are estimated to be living with chronic Hepatitis C worldwide. This growing patient population necessitates enhanced diagnostic and treatment solutions, thereby propelling market growth. The World Health Organization emphasizes the importance of early detection and effective treatment, which further underscores the need for innovative diagnostic technologies and antiviral therapies. Consequently, the market is projected to expand significantly, with a valuation of 46.5 USD Billion in 2024, reflecting the urgent demand for comprehensive Hepatitis C management.

    Growing Awareness and Education Programs

    The rising awareness regarding Hepatitis C and its implications is a crucial driver for the Global Hepatitis C Diagnosis and Treatment Market Industry. Educational programs aimed at informing the public about the risks, transmission, and treatment options for Hepatitis C are gaining momentum. Organizations and health authorities are actively promoting awareness campaigns that encourage individuals to seek testing and treatment. This heightened awareness is likely to lead to an increase in diagnosed cases, thereby driving demand for effective treatment options. As more individuals become informed about their health, the market is expected to experience substantial growth, aligning with the overall trend of increasing healthcare engagement.

    Increased Government Initiatives and Funding

    Government initiatives aimed at combating Hepatitis C are pivotal in driving the Global Hepatitis C Diagnosis and Treatment Market Industry. Many countries are implementing national strategies to eliminate Hepatitis C, which includes increased funding for screening programs and access to treatment. For example, the U.S. Centers for Disease Control and Prevention has launched campaigns to raise awareness and promote testing among high-risk populations. Such initiatives not only enhance public health outcomes but also stimulate market growth by increasing the demand for diagnostic and therapeutic solutions. The commitment to eradicate Hepatitis C is likely to sustain the market's upward trajectory, with a projected CAGR of 8.78% from 2025 to 2035.

    Key Companies in the Hepatitis C Diagnosis Treatment Market market include

    Industry Developments

    In India, Abbott introduced "LiverHealth," a project to make it easier to diagnose liver function and promote awareness about hepatitis C.

    The market is consolidated, with Gilead Sciences, Inc. accounting for roughly 80.1 percent of the market share, with the majority of revenue coming from the sales of the medications Harvoni and Sovaldi. Bristol-Myers Squibb Company and AbbVie Inc. are the other main participants.

    Future Outlook

    Hepatitis C Diagnosis Treatment Market Future Outlook

    The Hepatitis C Diagnosis and Treatment Market is projected to grow at 8.78% CAGR from 2024 to 2035, driven by advancements in diagnostic technologies, increased awareness, and enhanced treatment options.

    New opportunities lie in:

    • Developing point-of-care testing solutions to improve accessibility in remote areas.
    • Investing in telemedicine platforms for remote patient monitoring and consultations.
    • Forming strategic partnerships with biotech firms for innovative drug development.

    By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnosis and treatment methodologies.

    Report Scope

    Attribute/Metric Details
    Market Size 2023 44.2 (USD Billion)
    Market Size 2024 46.55 (USD Billion)
    Market Size 2032 82.34 (USD Billion)
    Compound Annual Growth Rate (CAGR) 12.56 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US)
      Key Market Opportunities The Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. \r\nAccording to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C
      Key Market Drivers Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    At what CAGR is the Hepatitis C diagnosis and treatment market projected to grow in the forecast period (2024-2032)?

    Hepatitis C diagnosis and treatment market is projected to grow at approximately 12.56% CAGR during the assessment period (2024-2032).

    What are the major tailwinds pushing the growth of the Hepatitis C diagnosis and treatment market?

    high prevalence and increasing awareness about the diseases are major tailwinds pushing the growth of the Hepatitis C diagnosis and treatment market.

    What are the key growth impeders of the Hepatitis C diagnosis and treatment market?

    Stringent government regulations and the availability of alternate treatment options are major growth impeders for the Hepatitis C diagnosis and treatment market.

    Which region holds the largest share in the Hepatitis C diagnosis and treatment market?

    North America holds the largest share in the Hepatitis C diagnosis and treatment market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the Hepatitis C diagnosis and treatment market?

    Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), Vertex Pharmaceuticals Incorporated (US), AbbVie Inc. (US), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US), Beckman Coulter, Inc. (US), Abbott (US), Siemens Medical Solutions USA, Inc. (Germany), DiaSorin SpA (Italy), MedMira Inc. (Canada), Qiagen (Germany), Hologic, Inc. (US), bioMérieux SA (France), and Bio-Rad Laboratories, Inc. (US), are some of the top players operating in the Hepatitis C diagnosis and treatment market.

    Hepatitis C Diagnosis and Treatment Market Research Report - Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials